Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05519085RecruitingPhase 3
Test mezigdomide vs pomalidomide with standard drugs for myeloma
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
Los Alamitos, CaliforniaAges 18 years+ - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Chandler, ArizonaAges 18–75 - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Gilbert, ArizonaAges 18 years+ - NCT05552755RecruitingPhase 1/Phase 2
Drug trial for FAP to reduce pre-cancer growth
This early-phase trial studies REC-4881 in adults with familial adenomatous polyposis (FAP), a condition that causes many colon/rectum and duodenal polyps. It aims to see whether the treatment can safely help control or shrink polyp growth in people who have had bowel surgery.
Scottsdale, ArizonaAges 18 years+ - NCT05557045RecruitingPhase 1
Trial of an oral pill for MAPK-driven advanced solid tumors
This Phase 1 study tests an oral investigational medicine (JZP815) to see how safe it is, the best dose, and whether it can shrink tumors. It’s for adults with advanced or metastatic solid cancers that have a specific MAPK pathway genetic change.
Los Angeles, CaliforniaAges 18 years+ - NCT05561647Recruiting
Survey of GATTEX knowledge for patients and prescribers
This study uses a survey to check how much people and doctors know about using GATTEX. It may help improve education and support for safer, more informed use of the medicine.
Cambridge, MassachusettsAges 18 years+ - NCT05583617RecruitingPhase 1/Phase 2
Testing multiple treatments for multiple myeloma after prior therapy
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Randwick, New South WalesAges 18 years+ - NCT05584722Recruiting
Study risk and resilience in pulmonary arterial hypertension
This study looks at how people with pulmonary arterial hypertension (PAH) and certain genetic risks cope and how their bodies respond over time. It may help researchers understand factors linked to better or worse outcomes, and how different people manage the condition.
Nashville, TennesseeAges 15–80 - NCT05587049Recruiting
Testing an oral medicine plus azacitidine to improve AML disease
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Medellín, AntioquiaAges 18 years+ - NCT05595434Recruiting
Studying stress and reality tracking in young adults
This study looks at how people track what’s real and how stress affects thinking and behavior. It may help researchers understand stress-related changes, using tasks involving listening and reading.
BronAges 18–30 - NCT05614739RecruitingPhase 1
Study drug for cancers with an FGFR3 gene change
This Phase 1 trial tests LOXO-435 in people with solid tumors that have an FGFR3 pathway gene alteration. It may help shrink or control cancer by targeting this specific gene change.
Tucson, ArizonaAges 18 years+ - NCT05626114RecruitingPhase 2
Study of a lab-made eye treatment after subretinal surgery
This Phase 2 study tests OpRegen, a treatment delivered during special eye surgery, for geographic atrophy related to age-related macular degeneration (GA from AMD). It also includes an imaging “substudy” that uses detailed pictures of your retina to better track safety and activity.
Beverly Hills, CaliforniaAges 50 years+ - NCT05640102Recruiting
Study of zanubrutinib in Waldenström macroglobulinemia
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Huntsville, AlabamaAges 18 years+ - NCT05648214RecruitingPhase 1/Phase 2
Testing a new liver medicine in people with fatty liver
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
Glendale, CaliforniaAges 18–75 - NCT05650996RecruitingPhase 1
Early hand therapy participation after broken wrist
This Phase 1 study looks at whether starting hand activity soon after a distal radius fracture helps improve recovery outcomes. You may be able to join if your broken wrist is treated with a cast and you can report your symptoms and function reliably in English.
Washington, VirginiaAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Duarte, CaliforniaAges 18 years+ - NCT05659901Recruiting
Study tracks symptoms and test results in PLP1-confirmed PMD
This study follows children with Pelizaeus-Merzbacher disease (PMD) who have a specific genetic change (PLP1 duplication). It aims to learn which body measurements (“biomarkers”) and symptoms change over time, to better understand disease progression.
Atlanta, GeorgiaAges 6 months–17 years - NCT05665998Recruiting
Brain-controlled spinal stimulation for arm rehab after neck injury
This study tests a brain-controlled spinal stimulation approach to improve arm (upper limb) movement after a neck spinal cord injury. It may help people who have very limited arm function after a stable, traumatic injury, using frequent training and device-related checks.
Lausanne, Canton of VaudAges 18–75 - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Los Angeles, CaliforniaAges 18 years+ - NCT05669950RecruitingPhase 1/Phase 2
Study drug Lu AG13909 for congenital adrenal hyperplasia
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
Ann Arbor, MichiganAges 18–70 - NCT05682378RecruitingPhase 3
Long-term follow-up for inclisiran in young people with inherited high cholesterol
This study follows people with HeFH or HoFH (inherited high cholesterol) who previously took inclisiran in specific pediatric ORION studies. It mainly checks long-term safety and how well the treatment continues to be tolerated over time.
Boca Raton, FloridaAges 12–100 - NCT05692388Recruiting
Study social needs support for Black adults with kidney and diabetes
This study looks at health-related social needs—like barriers to food, housing, or care—in African American adults living with type 2 diabetes and chronic kidney disease. It uses a mixed-methods approach to understand needs better and what support may help.
Milwaukee, WisconsinAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05704361RecruitingPhase 1
Testing a new MS medicine in people not on other treatments
This early-phase trial studies how well a new medicine (given through a vein or under the skin) is tolerated by the body in people with multiple sclerosis. It may help researchers learn whether it’s a safe option for MS, especially before comparing effects in later studies.
Stanford, CaliforniaAges 18–65
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.